Company description: GenomeDx Biosciences Inc. is a personalized medicine company focused on the development and commercialization of genomic based diagnostic and prognostic tools that analyze the biology of cancer to improve the treatment decision-making process by recognizing the importance of each patient’s unique set of genetic information.
Location: Canada, British Columbia, Vancouver
Investors 1
| Date | Name | Website |
| 17.07.2021 | Baird Capi... | bairdcapit... |
Mentions in press and media 8
| Date | Title | Description |
| 28.09.2015 | GenomeDx Biosciences Secures Expansion Financing from CRG | GenomeDx Biosciences, a company that develops a genomic test for predicting metastatic disease in men with prostate cancer, secured expansion financing from CRG, a healthcare investment firm, in the form of a senior secured term loan. The a... |
| 28.09.2015 | GenomeDx Biosciences Receives Debt Financing | San Diego-based GenomeDx Biosciences, a developer of annotated, genomics research information databases, has received an expansion financing from healthcare investor CRG, the company said this morning. Size of the funding was not announced.... |
| 25.09.2014 | Urologists v. Rad Oncs: New test shifts how doctors plan prostate cancer treatment | A test is important, GenomeDx CEO Doug Dolginow said, because the tumor can be quite aggressive and even if it’s surgically removed, radiation’s required. However, at present there isn’t a very reliable method to screen out how aggressive a... |
| 30.09.2013 | GenomeDX Gets New Funding | San Diego-based GenomeDX Biosciences said this morning that it has raised a Series B financing round, for the company's genomic tests for prostate cancer. The funding was led by Merck Global Health Innovation Fund (GHIF), and also included ... |
| 09.01.2012 | GenomeDx Biosciences Closes Series A Financing Round | GenomeDx Biosciences Inc., a Vancouver, BC, Canada-based molecular diagnostic company, has closed a Series A financing round of undisclosed amount. The round was co-led by Baird Venture Partners and aeris CAPITAL, with participation from CD... |
| 09.01.2012 | GenomeDx Biosciences Closes Series A | VANCOUVER, BRITISH COLUMBIA, Molecular diagnostic company announced it has closed a Series A financing round led by Baird Venture Partners, the U.S. venture capital fund of Baird Private Equity, and aeris CAPITAL AG. CD Ventures and indiv... |
| 28.11.2007 | Life sciences briefing: Wednesday, Nov. 28, 2007 | Featured companies: American Aerogel, Clinicient, Frazier Healthcare Ventures, Genome Diagnostics, RadPharm, RainDance Technologies, Vivacta UPDATED: Expanded items on Vitae, RadPharm, Vivacta and Genome Diagnostics. Intelligent Bio-Systems... |
| - | Urologists v. Rad Oncs: New test shifts how doctors plan prostate cancer treatment | There are myriad prostate cancer screeners on the market, but a San Diego company’s test has an interesting spin: Researchers have found that the results of GenomeDx’s Decipher diagnostic shifts the way physicians recommend treatment for th... |